Tumor mutational burden (TMB): a predictive biomarker for lung cancer immunotherapy response - 102017

Spotlight
Video

Tumor mutational burden (TMB): a predictive biomarker for lung cancer immunotherapy response

VJOncology has 824 videos Subscribe Here

Loading........
Description: Tumor mutational burden (TMB) is emerging as a promising predictive biomarker for lung cancer immunotherapy response. Here, Fred Hirsch, MD, PhD, of University of Colorado, Denver, CO, discusses the data available on this method so far and the further analysis that he thinks is needed, in terms of both evaluation and the complex issue of assay standardization. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.
Shared By : VJOncology
Posted on : 02/06/18
Added : 9 months ago
Category : General